This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known which treatment regimen is more effective for melanoma. This randomized Phase III trial is studying peptide vaccine therapy and/or sargramostim and comparing how well they work in treating patients with locally advanced or metastatic melanoma. Since it is not known if any of these treatments are effective for melanoma patients who have been surgically rendered free of disease, but who remain at very high risk for disease recurrence, this study is placebo controlled. Thus, some patients will receive the experimental treatment and some patients will receive a placebo. The treatments will be compared to see if any of these treatments help melanoma patients live longer or have a longer time before the melanoma recurs.
Showing the most recent 10 out of 459 publications
